231 related articles for article (PubMed ID: 22440042)
1. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.
Feng M; Smith DE; Normolle DP; Knol JA; Pan CC; Ben-Josef E; Lu Z; Feng MR; Chen J; Ensminger W; Lawrence TS
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1441-7. PubMed ID: 22440042
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases.
Robertson JM; McGinn CJ; Walker S; Marx MV; Kessler ML; Ensminger WD; Lawrence TS
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1087-92. PubMed ID: 9392548
[TBL] [Abstract][Full Text] [Related]
3. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
[TBL] [Abstract][Full Text] [Related]
5. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
6. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
7. Predictive models for regional hepatic function based on 99mTc-IDA SPECT and local radiation dose for physiologic adaptive radiation therapy.
Wang H; Feng M; Frey KA; Ten Haken RK; Lawrence TS; Cao Y
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):1000-6. PubMed ID: 23688813
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
9. The relationship between local dose and loss of function for irradiated lung.
Gopal R; Tucker SL; Komaki R; Liao Z; Forster KM; Stevens C; Kelly JF; Starkschall G
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):106-13. PubMed ID: 12694828
[TBL] [Abstract][Full Text] [Related]
10. Proton Beam Therapy in Liver Malignancies.
Siddiqui O; Pollock A; Samanta S; Kaiser A; Molitoris JK
Curr Oncol Rep; 2020 Feb; 22(3):30. PubMed ID: 32108284
[TBL] [Abstract][Full Text] [Related]
11. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
[TBL] [Abstract][Full Text] [Related]
13. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
[TBL] [Abstract][Full Text] [Related]
14. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Wo JY; Dawson LA; Zhu AX; Hong TS
Surg Oncol Clin N Am; 2014 Apr; 23(2):353-68. PubMed ID: 24560114
[TBL] [Abstract][Full Text] [Related]
15. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
17. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.
Symon Z; Levi M; Ensminger WD; Smith DE; Lawrence TS
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):473-8. PubMed ID: 11380236
[TBL] [Abstract][Full Text] [Related]
18. Impact of pretreatment cholinesterase level on survival of inoperable intrahepatic or hepatic-hilar carcinomas treated with three-dimensional conformal radiotherapy.
Hamamoto Y; Niino K; Ishiyama H; Hosoya T
Radiat Med; 2004; 22(5):316-23. PubMed ID: 15553012
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
Ben-Josef E; Han S; Tobi M; Shaw LM; Bonner HS; Vargas BJ; Prokop S; Stamos B; Kelly L; Biggar S; Kaplan I
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1160-4. PubMed ID: 12128116
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers.
Robertson JM; Lawrence TS; Andrews JC; Walker S; Kessler ML; Ensminger WD
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):325-30. PubMed ID: 9069303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
